Novadip Biosciences
Novadip Biosciences is dedicated to advancing the standard of care in bone and tissue regenerative medicine through innovative, single-treatment cures. Founded in 2013 as a spin-off from Université Catholique de Louvain and Saint Luc University Hospital, the company leverages its proprietary 3M3 tissue regeneration platform to develop regenerative tissue products that accelerate healing of large bone defects, non-union, and spine fusion. With a focus on patient-centric solutions, Novadip aims to transform lives by providing effective treatments for conditions such as congenital pseudarthrosis of the tibia (CPT), bone non-union, and spinal issues.
Industries
Nr. of Employees
small (1-50)
Novadip Biosciences
Mont-saint-guibert, Brabant Wallon, Belgium, Europe
Products
Autologous adipose-derived cellular graft for critical-size bone reconstruction
A moldable, cellular autologous graft composed of differentiated adipose-derived stem cells within a 3D extracellular matrix, intended as a single-treatment therapy to promote bone union in critical-size defects and rare pediatric indications.
Off-the-shelf allogeneic, cell-free matrix for bone grafting and spinal fusion
A lyophilized, sterilized allogeneic matrix product containing bioactive matrix factors (no viable cells) designed for common orthopedic procedures including spinal fusion and traumatic bone non-union.
Cell-free miRNA/exosome therapeutic candidates for tissue rejuvenation and oncology
Purified miRNA/exosome preparations manufactured from differentiated stem cells for applications in skin/tissue rejuvenation and as potential therapeutics in certain solid tumors.
Autologous adipose-derived cellular graft for critical-size bone reconstruction
A moldable, cellular autologous graft composed of differentiated adipose-derived stem cells within a 3D extracellular matrix, intended as a single-treatment therapy to promote bone union in critical-size defects and rare pediatric indications.
Off-the-shelf allogeneic, cell-free matrix for bone grafting and spinal fusion
A lyophilized, sterilized allogeneic matrix product containing bioactive matrix factors (no viable cells) designed for common orthopedic procedures including spinal fusion and traumatic bone non-union.
Cell-free miRNA/exosome therapeutic candidates for tissue rejuvenation and oncology
Purified miRNA/exosome preparations manufactured from differentiated stem cells for applications in skin/tissue rejuvenation and as potential therapeutics in certain solid tumors.
Services
Clinical development and trial collaboration
Design and execution of early-phase clinical studies and compassionate-use treatments for regenerative orthopedics and related indications.
Clinical-scale manufacturing and supply for autologous/allogeneic products
GMP manufacturing and supply chain services to produce autologous cell grafts and off-the-shelf allogeneic matrices for clinical programs and distribution.
Partnerships and commercialization support
Business development and partnership engagement to advance development programs, pursue licensing and distribution, and support commercialization planning.
Clinical development and trial collaboration
Design and execution of early-phase clinical studies and compassionate-use treatments for regenerative orthopedics and related indications.
Clinical-scale manufacturing and supply for autologous/allogeneic products
GMP manufacturing and supply chain services to produce autologous cell grafts and off-the-shelf allogeneic matrices for clinical programs and distribution.
Partnerships and commercialization support
Business development and partnership engagement to advance development programs, pursue licensing and distribution, and support commercialization planning.
Expertise Areas
- Tissue regeneration using adipose-derived stem cells
- Autologous cell therapy development and manufacturing
- Allogeneic off-the-shelf biologic matrix development
- miRNA/exosome therapeutics discovery and production
Key Technologies
- Three-dimensional scaffold-free extracellular matrix
- Adipose-derived stem cell differentiation
- miRNA/exosome production and purification
- Lyophilization and terminal sterilization for cell-free matrices